The trailing P/E of -0.31 is not meaningful as a valuation anchor given losses, so the forward EV/EBITDA of 6.71 versus peers such as CF at 6.22 and Corteva at 13.43 is the more useful reference point. The 0.34x price-to-book reflects equity that has nearly been consumed by cumulative losses, which suggests the market is pricing in substantial further impairment risk. Investors should monitor whether forward EBITDA estimates hold before treating the apparent discount as an entry opportunity.

The swing from a 40%-plus gross margin through 2025 to negative gross margin suggests high-cost inventory being liquidated below cost, consistent with channel destocking rather than a pure loss of pricing power. The gap between operating losses and net losses points to large non-operating or one-time items that distort reported EPS of -15.54. Normalized earnings power is therefore difficult to establish from the reported data and should be assessed after stripping out impairment and restructuring effects.

With equity near zero, the reported debt-to-equity ratio loses analytical meaning, though the direction clearly indicates eroded financial flexibility. The interest coverage ratio of -8.58 in the latest quarter reflects operating losses rather than debt service capacity, which warrants further investigation before any conclusion on refinancing exposure. Investors should monitor covenant headroom and debt maturity schedules, as the reported figures alone cannot confirm the severity of refinancing risk.

The current ratio declined from 1.99 in 2026Q2 to 1.66 while the cash balance of $735.8M provides a meaningful buffer against near-term obligations. However, the 2026Q3 operating cash flow of $56.6M coincided with a large working capital inflow, suggesting headline liquidity may be flattered by balance sheet unwinds. Under severe stress with continued losses, the buffer could erode quickly, and the position should be stress-tested against a scenario of sustained negative operating cash flow.